Figure 3.

Inhibition of RGO-SMEDDS on migration, invasion, and angiogenesis of hepatocellular carcinoma (HCC)

(A and B) Representative image of Transwell cell migration and invasion assay in Huh7 and HepG2 cells treated with or without RGO-SMEDDS, ×100 magnification. Scale bars, 50 μm. (C) The antiangiogenic ability of RGO-SMEDDS to Huh7 and HepG2 cells detected by tubule formation assay, ×100 magnification. Scale bars, 50 μm. (D) qRT-PCR analyses exhibit the mRNA levels of VEGF and VEGFR in RGO-SMEDDS-treated and untreated HCC. (E) Protein expression level of VEGF and VEGFR in HCC treated with RGO-SMEDDS by WB assay. (F) Representative IHC staining images of CD34, VEGF, and VEGFR in xenograft tumor. Scale bars, 50 μm. Values are shown as mean ± standard error from three independent experiments. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.